Paediatrics

Group leader

María Jesús del Cerro Marín

mjesus.cerro(ELIMINAR)@salud.madrid.org

Tlf.: +34 91 3369027

Collaborators

  • Enrique Otheo de Tejada Barasoain
  • María Álvarez Fuente
  • Mª Elvira Garrido-Lestache Rodríguez-Monte
  • Luis Fernando Rivilla Parra
  • María Belén Roldán Martín
  • Inmaculada Sánchez Pérez
  • Rocío Tamaríz-Martel Moreno
  • Beatriz García Cuartero
  • Alexandra Villagrá Albert
  • Isabel Molina Borao
  • Natalia Rivero Jiménez
  • María Toledano Navarro

Group leader

María Jesús del Cerro Marín

mjesus.cerro(ELIMINAR)@salud.madrid.org

Tlf.: +34 91 3369027

Collaborators

  • Enrique Otheo de Tejada Barasoain
  • María Álvarez Fuente
  • Mª Elvira Garrido-Lestache Rodríguez-Monte
  • Luis Fernando Rivilla Parra
  • María Belén Roldán Martín
  • Inmaculada Sánchez Pérez
  • Rocío Tamaríz-Martel Moreno
  • Beatriz García Cuartero
  • Alexandra Villagrá Albert
  • Isabel Molina Borao
  • Natalia Rivero Jiménez
  • María Toledano Navarro

Strategic objectives

  • Development of new therapies for the prevention of bronchopulmonary dysplasia.
  • Evaluation of new therapies in pulmonary arterial hypertension (PAH).
  • Evaluation of new drugs in paediatrics.
  • Prognosis and quality of life of congenital cardiopathies in the medium and long term.
  • Genetic mapping of diabetes mellitus, type 1.
  • Development, implementation and dissemination of new technologies in diabetes mellitus, type 1 in childhood and adolescence.
  • New insulins in diabetes mellitus, type 1 in childhood and adolescence.
  • Lifestyle, prevention and treatment in child obesity.
  • Epidemiology and genetic analysis of frequent diseases: pseudohypoparathyroidism (PHP GROUP), monogenic diabetes.
  • Epidemiological studies on efficacy and safety in children with treatment with growth hormone.
  • Hyperandrogenism and type 1 diabetes.

Research lines

  • Pulmonary arterial hypertension.
  • Cell therapy in bronchopulmonary dysplasia.
  • Markers for prediction of the risk of developing bronchopulmonary dysplasia.
  • New drug safety approaches in the paediatric population.
  • Adolescent and adult congenital cardiopathies.
  • New technologies in type 1 diabetes.
  • New drugs in type 1 diabetes in childhood and adolescence.
  • Epidemiology and safety of paediatric hospital infections.
  • Hyperandrogenism and diabetes mellitus, type 1.
  • Pituitary tumours in children and adolescents.

Location

Paediatrics Department

11th floor right
Ramón y Cajal University Hospital

Keywords

bronchopulmonary dysplasia, cell therapy, pulmonary arterial hypertension, congenital cardiopathies, diabetes mellitus, infrequent diseases, childhood obesity, new technologies in type 1 diabetes, growth, drug safety in pediatrics, hospital infection, hyperandrogenism